Navigation Links
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Date:2/15/2008

hese cancers in addition to prostate cancer."

In the combination Phase 1 dose-escalating study, 33 patients were treated with one of four doses (60, 80, 100 or 120 mg/m squared) of picoplatin, as well as either 60 mg/m squared or 75 mg/m squared (full-dose) docetaxel plus 5 mg prednisone twice daily. Nine patients received 120 mg/m squared picoplatin and 75 mg/m squared docetaxel every 21 days plus 5 mg prednisone twice daily. This dose, which is also the dose currently under study in the Phase 2 trial, was well tolerated.

Hematological toxicity, including neutropenia, anemia and thrombocytopenia, was dose-dependent and reversible. Neutropenia was the dose-limiting toxicity (DLT). Mild neuropathy (grade 1) was observed in 3 of 33 patients (9 percent) and was unrelated to cumulative picoplatin dose. Neuropathy was infrequent, and no neuropathy of grade 2 or greater was observed. PSA response rate was 65 percent (20 of 31 evaluable patients). Survival data are not yet available. Patient withdrawal from study treatment occurred from death in four patients, progressive disease in eight patients, and withdrawal of consent in one patient. Patients in the Phase 1 trial received a median number of 7 cycles, and 13 of 33 patients completed the maximum of 10 cycles of treatment according to the study protocol.

Based on safety and efficacy data from the Phase 1 study, the recommended Phase 2 regimen of intravenous picoplatin (120 mg/m squared) and docetaxel (75 mg/m squared) every 21 days with prednisone (5 mg) orally twice daily is being evaluated in a Phase 2 study in chemotherapy naive mHRPC patients. PSA response is the primary endpoint; secondary endpoints include radiological response using RECIST criteria, time to progression and survival (1-year, progression-free and overall). The Phase 2 trial completed enrollment in December 2007. The Company expects to present the results of this study in scientific forums later this year.

About Picoplati
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Research and Markets ... the "Global and Chinese Hemodialysis Concentrates Industry ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , Global ... a professional and in-depth study on the current ... focus on the Chinese situation. The ...
(Date:10/25/2014)... 2014  In 2008, two of Dr. Gurney,s employees ... controlled substances, on a regular basis, that were not ... Gurney was practicing "all the time" while under the ... employees said that Dr. Gurney was prone to "making ... Dr. Gurney,s behavior became increasingly erratic and unfocused, ...
(Date:10/25/2014)... CUPERTINO, Calif. , Oct. 24, 2014 ... ) third quarter 2014 financial results press release, you ... will be broadcast live over the internet on Monday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
... Jan. 12, 2011 Webmedx , the third largest ... provider in the U.S., today announced it has received the ... the 2010 Top 20 Best in KLAS Awards: Software ... Best in KLAS 2010 award, the company was also rated ...
... 2011 RESMED INC. (NYSE: RMD ), announced ... its results for the second quarter and six months of ... with ResMed,s results will be issued after 1:00 p.m. pacific ... webcast to review its results, market trends, and future outlook. ...
Cached Medicine Technology:Webmedx Named Best in KLAS and Ranked #1 Transcription Services Vendor for Second Year in a Row 2Webmedx Named Best in KLAS and Ranked #1 Transcription Services Vendor for Second Year in a Row 3ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results 2
(Date:10/25/2014)... The global HCIT outsourcing market is ... reach $50.4 billion by 2018 from $35 billion in ... pharmaceutical industry are driving the HCIT outsourcing market. These ... focus on core business, reduce operational and maintenance costs, ... reducing hiring and training costs), share risk, and quickly ...
(Date:10/25/2014)... 25, 2014 TASC (Total Administrative ... other benefits account management services, announces the release ... save on taxes, reduce administrative workload, and lessen ... savings and the efficient handling of complex, time-sensitive, ... that best meets their goals and objectives. The ...
(Date:10/25/2014)... October 25, 2014 Homeowners that are ... ‘gone bad’ need wonder no more. Clean Crawls ... should watch out for when it comes to insulation ... to the article released by Clean Crawls, can cause ... that any insulation that has deteriorated, become damp, or ...
(Date:10/25/2014)... -- Interrupting blood supply to an arm or a leg ... the surgery, according to a new study. "During ... the heart to be able to operate on it. After ... ability to produce energy because it doesn,t get oxygen. When ... such as an arm or a leg, the body prepares ...
(Date:10/25/2014)... 2014 (HealthDay News) -- A large influx of international ... to avoid tens of thousands of deaths from the ... predict. Using a specially designed mathematical model, ... outbreak in just one densely populated county of hard-hit ... of Monrovia. The researchers said that if international ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
... due to disease, accident or disasters like the tsunami will ... the invitation of a non-resident Indian association, we are organising ... people will be fitted with the Jaipur Foot," D.R. Mehta, ... Jaipur, told IANS here. ,He said the ...
... about our weight or a bad hair day is ... disorders spend// nearly every waking moment--up to 80 to ... treatment professionals with the Eating Disorders Program at The ... the concern with body shape and size that is ...
... of ADHD drugs to indicate the contra indications clearly to ... ,Dr. Steven Galson, director of the FDA’s Center ... are immensely useful in treating patients with ADHD, the risks ... also said that FDA is working in tandem with drug ...
... (AMD) is the leading cause of visual impairment and ... two million people. ,The American Academy ... is incurable, there are new treatments that can usually ... the disease. ,The Academy encourages those older ...
... a safe and healthy multivitamin? Vitamins and Minerals: What ... Medical School//, offers the following advice. ,Look ... the U.S. Pharmacopeia Dietary Supplement Verification Program (USP-DSVP) mark, ... standards. ,Consider safe levels. All dietary ...
... health in India has immensely deteriorated over the last seven ... top UNICEF officials said Wednesday. ,According to the ... in the age group between 15 and 49 were anemic ... ,Anemia is a deficiency of red blood cells, which can ...
Cached Medicine News:Health News:Indonesians to Be Fitted Jaipur-made Artificial Limbs 2Health News:Improving Body Image Key to Treating Eating Disorders 2Health News:Improving Body Image Key to Treating Eating Disorders 3Health News:Spring is Time for Age-Related Macular Degeneration (AMD) Awareness 2Health News:Married Women, Children Most Anemic in India 2